The four-component meningococcal serogroup B vaccine (4CMenB; Bexsero, Novartis) is the first successful vaccine against the endemic form of this cause of serious bacterial meningitis and septicaemia. The vaccine has been in development for almost two decades and has been approved by licensing authorities in Europe, Canada, and Australia. But it is only now moving towards incorporation into routine infant immunisation programmes following a recommendation from the UK Joint Committee on Vaccination and Immunisation (JCVI), with the proviso that a cost-effective price be negotiated.